Inventor
TRAVERSARI CATIA
IT23 patents
⚠️ This page may combine multiple inventors who share the name “TRAVERSARI CATIA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
LUDWIG INST CANCER RES
21 patentsUS5405940AApr 11, 1995
Isolated nonapeptides derived from MAGE genes and uses thereof
LUDWIG INST CANCER RES129 citations98
US5342774AAug 30, 1994
Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
LUDWIG INST CANCER RES232 citations98
US6034214AMar 7, 2000
Isolated nonapeptides which bind to HLA molecules and provoke lysis by cytolytic T cells
LUDWIG INST CANCER RES40 citations96
US5620886AApr 15, 1997
Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
LUDWIG INST CANCER RES75 citations96
US5462871AOct 31, 1995
Isolated nucleic acid molecules which encode MAGE derived nonapeptides
LUDWIG INST CANCER RES52 citations96
US6488932B1Dec 3, 2002
Method for treating cancer by administering MAGE-derived peptides
LUDWIG INST CANCER RES25 citations92
US6201111B1Mar 13, 2001
Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursors
LUDWIG INST CANCER RES15 citations92
US5925729AJul 20, 1999
Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
LUDWIG INST CANCER RES31 citations92
US5854203ADec 29, 1998
Tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
LUDWIG INST CANCER RES25 citations92
US5837476ANov 17, 1998
Methods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursor
LUDWIG INST CANCER RES19 citations92
US5695994ADec 9, 1997
Isolated cytolytic T cells specific for complexes of MAGE related peptides and HLA molecules
LUDWIG INST CANCER RES20 citations91
US5554506ASep 10, 1996
Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
LUDWIG INST CANCER RES31 citations91
US6531451B1Mar 11, 2003
Tumor antigens and CTL clones isolated by a novel procedure
LUDWIG INST CANCER RES24 citations89
US5856091AJan 5, 1999
Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
LUDWIG INST CANCER RES16 citations82
US6379901B1Apr 30, 2002
Method for screening for cancer using binders for MAGE related peptides and complexes of the peptide and HLA molecules
LUDWIG INST CANCER RES12 citations72
US6353089B1Mar 5, 2002
Method for stimulating CTLs with peptides
LUDWIG INST CANCER RES6 citations72
US6019987AFeb 1, 2000
Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
LUDWIG INST CANCER RES7 citations72
US6001975ADec 14, 1999
Precursor processed to at least one tumor rejection antigen presented by HLA-A2
LUDWIG INST CANCER RES15 citations72
US6222012B1Apr 24, 2001
Isolated nonapeptides presented by HLA molecules, and uses thereof
LUDWIG INST CANCER RES10 citations71
USRE40089EFeb 19, 2008
Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor
LUDWIG INST CANCER RES0 citations52
US7923534B1Apr 12, 2011
Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3
LUDWIG INST CANCER RES0 citations51